Website intended for a NZ health professional readership
This article discusses the five influenza vaccines available for this year’s flu season, with focus on a new cell-based option
1. Tenforde MW, Patel MM, Lewis NM, et al. Vaccine effectiveness against influenza A(H3N2)-associated hospitalized illness: United States, 2022. Clin Infect Dis 2023;76(6):1030–37.
2. Sullivan SG, Chilver MB, Carville KS, et al. Low interim influenza vaccine effectiveness, Australia, 1 May to 24 September 2017. Euro Surveill 2017;22(43):17-00707.
3. Boikos C, Fischer L, O’Brien D, et al. Relative effectiveness of the cell-derived inactivated quadrivalent influenza vaccine versus egg-derived inactivated quadrivalent influenza vaccines in preventing influenza-related medical encounters during the 2018-2019 influenza season in the United States. Clin Infect Dis 2021;73(3):e692–98.
4.ESR. Recommendation for Seasonal Influenza Vaccine Composition for New Zealand for 2024. October 2023. https://www.esr.cri.nz/digital-library/influenza-vaccine-recommendations-report-for-2024/
5. Sah P, Medlock J, Fitzpatrick MC, et al. Optimizing the impact of low-efficacy influenza vaccines. Proc Natl Acad Sci U S A 2018;115(20):5151–56.
6. Coleman BL, Gutmanis I, McGovern I, Haag M. Effectiveness of cell-based quadrivalent seasonal influenza vaccine: A systematic review and meta-analysis. Vaccines (Basel) 2023;11(10):1607.
7. Boikos C, Sylvester GC, Sampalis JS, Mansi JA. Relative effectiveness of the cell-cultured quadrivalent influenza vaccine compared to standard, egg-derived quadrivalent influenza vaccines in preventing influenza-like illness in 2017-2018. Clin Infect Dis 2020;71(10):e665–71.
8. Divino V, Krishnarajah G, Pelton SI, et al. A real-world study evaluating the relative vaccine effectiveness of a cell-based quadrivalent influenza vaccine compared to egg-based quadrivalent influenza vaccine in the US during the 2017-2018 influenza season. Vaccine 2020;38;6334–43.
9. Krishnarajah G, Divino V, Postma MJ, et al. Clinical and economic outcomes associated with cell-based quadrivalent influenza vaccine vs. standard-dose egg-based quadrivalent influenza vaccines during the 2018–2019 influenza season in the United States. Vaccines (Basel) 2021;9(2):80.
10. Boikos C, McGovern I, Molrine D, et al. Review of analyses estimating relative vaccine effectiveness of cell-based quadrivalent influenza vaccine in three consecutive US influenza seasons. Vaccines (Basel) 2022;10(6):896.
Pharmacist prescribers Linda Bryant and Leanne Te Karu discuss positive polypharmacy for heart failure. Current evidence shows the intensive implementation of four medications offers the greatest benefit to most patients with heart failure, with significant reductions in cardiovascular mortality, heart failure hospitalisations and all-cause mortality
